Medindia

X

Replidyne to Report First Quarter 2008 Earnings

Wednesday, April 30, 2008 General News J E 4
Advertisement
LOUISVILLE, Colo., April 29 Replidyne, Inc.(Nasdaq: RDYN) announced today that it will hold a conference call onWednesday, May 7, 2008 at 4:45 P.M. ET to report first quarter 2008 earnings.On Thursday, May 8, 2008 at 4:00 P.M. ET Replidyne will host its annualshareholder meeting at Company headquarters at 1450 Infinite Drive inLouisville, CO.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering,developing, in-licensing and commercializing innovative anti-infectiveproducts. Replidyne's most advanced product candidate, faropenem medoxomil, isa novel oral community antibiotic, expected to be appropriate for use as afirst-line antibiotic for treatment of respiratory and skin infections inadult and pediatric patients. Replidyne's investigational antibacterial agentREP3123 targets Gram-positive C. difficile bacteria and C. difficile Infection(CDI). Replidyne is pursuing the development of other novel anti-infectiveprograms based on its DNA replication inhibition technology and its in-housediscovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates andexpectations that constitute forward-looking statements about Replidyne, Inc.that involve significant risks and uncertainties. Actual results could differmaterially from those discussed due to a number of factors including, thesuccess and timing of pre-clinical studies and clinical trials; the Company'sability to obtain a new partner for faropenem on acceptable terms; theCompany's ability to obtain and maintain regulatory approval of productcandidates and the labeling under any approval that may be obtained; plans todevelop and commercialize product candidates; the loss of key scientific ormanagement personnel; the size and growth of the potential markets for theCompany's product candidates and the Company's ability to serve those markets;regulatory developments in the U.S. and foreign countries; the rate and degreeof market acceptance of any future products; the accuracy of Company estimatesregarding expenses, future revenues and capital requirements; the Company'sability to obtain and maintain intellectual property protection for ourproduct candidates; the successful development of the Company's sales andmarketing capabilities; the success of competing drugs that are or becomeavailable; and the performance of third party manufacturers. These andadditional risks and uncertainties are described more fully in the Company'smost recent Form 10-K filed with the SEC under the Securities Exchange Act of1934. Copies of filings made with the SEC are available through the SEC'selectronic data gathering analysis and retrieval system (EDGAR) athttp://www.sec.gov. All forward-looking statements made in the press releaseare made as of the date hereof and the Company assumes no obligation to updatethe forward-looking statements in the document.Earnings conference call information is as follows: Kenneth J. Collins, President and CEO, and other members of Replidyne's management team will discuss earnings results via conference call and webcast on Wednesday, May 7, 2008, at 4:45 P.M. ET. Callers may participate in the conference call by dialing 866-770-7125 (domestic) or 617-213-8066 (international), and providing the passcode 79991920. To access the live webcast, please log on to the Company's website at http://www.Replidyne.com and go to the Investor Relations section. A replay of the conference call will be available approximately one hour after completion of the call through Wednesday, May 21, 2008 at midnight. Callers may access the replay by dialing 888-286-8010 (U.S. participants) or 617-801-6888 (international participants). The audio replay passcode is 81984297. To access a replay of the webcast, visit the Investor Relations section of the Company's website at
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Covance Inc. Invites You to Join the Webcast of It...
S
Rigel's R788 Slows Progression of Murine Lupus in ...